JP2010522770A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522770A5 JP2010522770A5 JP2010501246A JP2010501246A JP2010522770A5 JP 2010522770 A5 JP2010522770 A5 JP 2010522770A5 JP 2010501246 A JP2010501246 A JP 2010501246A JP 2010501246 A JP2010501246 A JP 2010501246A JP 2010522770 A5 JP2010522770 A5 JP 2010522770A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- methyl
- amino
- ethyl
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 21
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 13
- 208000032839 leukemia Diseases 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 241000124008 Mammalia Species 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 6
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 6
- 208000034578 Multiple myelomas Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- -1 2-amino-1-benzylethyl Chemical group 0.000 claims 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000012609 Cowden disease Diseases 0.000 claims 3
- 201000002847 Cowden syndrome Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 206010014967 Ependymoma Diseases 0.000 claims 3
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 3
- 208000036566 Erythroleukaemia Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 3
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 claims 3
- 208000032612 Glial tumor Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 3
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 3
- 206010027406 Mesothelioma Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 208000001715 Osteoblastoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000007452 Plasmacytoma Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000000389 T-cell leukemia Diseases 0.000 claims 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 206010047741 Vulval cancer Diseases 0.000 claims 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 3
- 208000008383 Wilms tumor Diseases 0.000 claims 3
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 3
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 claims 3
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 3
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 3
- 201000011143 bone giant cell tumor Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 208000003747 lymphoid leukemia Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000008026 nephroblastoma Diseases 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 201000008968 osteosarcoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 201000005102 vulva cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- ABFYOLRRAFQHQQ-UHFFFAOYSA-N 2-(aminomethyl)-n-[3-(2-methylpyrazol-3-yl)phenyl]-3-phenylpropanamide Chemical compound CN1N=CC=C1C1=CC=CC(NC(=O)C(CN)CC=2C=CC=CC=2)=C1 ABFYOLRRAFQHQQ-UHFFFAOYSA-N 0.000 claims 1
- RMFMLWLATFRKRL-UHFFFAOYSA-N 3-amino-n-[3-chloro-4-(2-methylpyrazol-3-yl)phenyl]-2-phenylpropanamide Chemical compound CN1N=CC=C1C(C(=C1)Cl)=CC=C1NC(=O)C(CN)C1=CC=CC=C1 RMFMLWLATFRKRL-UHFFFAOYSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- GQISJJJEEUSDGE-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-2-(2-methylpyrazol-3-yl)pyridine-4-carboxamide Chemical compound CN1N=CC=C1C1=CC(C(=O)NC(CN)CC=2C=CC=CC=2)=CC=N1 GQISJJJEEUSDGE-UHFFFAOYSA-N 0.000 claims 1
- HGCDGSLJOMAFRM-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-4-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CC=NC(C(=O)NC(CN)CC=2C=CC=CC=2)=C1 HGCDGSLJOMAFRM-UHFFFAOYSA-N 0.000 claims 1
- MUVATXQVQPISGR-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-4-(4-chloro-2-methylpyrazol-3-yl)-3-fluorobenzamide Chemical compound CN1N=CC(Cl)=C1C1=CC=C(C(=O)NC(CN)CC=2C=CC=CC=2)C=C1F MUVATXQVQPISGR-UHFFFAOYSA-N 0.000 claims 1
- DLHNYXVQHKMGKF-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-4-chloro-5-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CN=C(C(=O)NC(CN)CC=2C=CC=CC=2)C=C1Cl DLHNYXVQHKMGKF-UHFFFAOYSA-N 0.000 claims 1
- QPUOHBGHGDEPMW-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-5-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CC=C(C(=O)NC(CN)CC=2C=CC=CC=2)N=C1 QPUOHBGHGDEPMW-UHFFFAOYSA-N 0.000 claims 1
- JSPQRQRUUQWTNH-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-5-(2-methylpyrazol-3-yl)pyridine-3-carboxamide Chemical compound CN1N=CC=C1C1=CN=CC(C(=O)NC(CN)CC=2C=CC=CC=2)=C1 JSPQRQRUUQWTNH-UHFFFAOYSA-N 0.000 claims 1
- POTWYJVVEVBILJ-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-6-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CC=CC(C(=O)NC(CN)CC=2C=CC=CC=2)=N1 POTWYJVVEVBILJ-UHFFFAOYSA-N 0.000 claims 1
- ZVLYNYOWUKBHCQ-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-6-(2-methylpyrazol-3-yl)pyridine-3-carboxamide Chemical compound CN1N=CC=C1C1=CC=C(C(=O)NC(CN)CC=2C=CC=CC=2)C=N1 ZVLYNYOWUKBHCQ-UHFFFAOYSA-N 0.000 claims 1
- LOMQBYIMIXOIDD-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-6-chloro-5-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CC=C(C(=O)NC(CN)CC=2C=CC=CC=2)N=C1Cl LOMQBYIMIXOIDD-UHFFFAOYSA-N 0.000 claims 1
- YADDXIZKYVHMMQ-KRWDZBQOSA-N n-[(2s)-1-amino-3-(3-fluorophenyl)propan-2-yl]-4-(3-methyltriazol-4-yl)benzamide Chemical compound CN1N=NC=C1C1=CC=C(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)C=C1 YADDXIZKYVHMMQ-KRWDZBQOSA-N 0.000 claims 1
- GFICRIUQSAJGRZ-HNNXBMFYSA-N n-[(2s)-1-amino-3-[2-(trifluoromethyl)phenyl]propan-2-yl]-3-bromo-4-(2-methylpyrazol-3-yl)benzamide Chemical compound CN1N=CC=C1C1=CC=C(C(=O)N[C@H](CN)CC=2C(=CC=CC=2)C(F)(F)F)C=C1Br GFICRIUQSAJGRZ-HNNXBMFYSA-N 0.000 claims 1
- RMJUJMNPNFPQGP-HNNXBMFYSA-N n-[(2s)-1-amino-3-[2-(trifluoromethyl)phenyl]propan-2-yl]-3-fluoro-4-(2-methylpyrazol-3-yl)benzamide Chemical compound CN1N=CC=C1C1=CC=C(C(=O)N[C@H](CN)CC=2C(=CC=CC=2)C(F)(F)F)C=C1F RMJUJMNPNFPQGP-HNNXBMFYSA-N 0.000 claims 1
- ZFTLBMUSFJFDDC-INIZCTEOSA-N n-[(2s)-1-amino-3-[2-(trifluoromethyl)phenyl]propan-2-yl]-4-(2-methyl-1,2,4-triazol-3-yl)benzamide Chemical compound CN1N=CN=C1C1=CC=C(C(=O)N[C@H](CN)CC=2C(=CC=CC=2)C(F)(F)F)C=C1 ZFTLBMUSFJFDDC-INIZCTEOSA-N 0.000 claims 1
- SMXXLWMICRQSSN-ZDUSSCGKSA-N n-[(2s)-1-amino-3-[2-(trifluoromethyl)phenyl]propan-2-yl]-4-chloro-5-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CN=C(C(=O)N[C@H](CN)CC=2C(=CC=CC=2)C(F)(F)F)C=C1Cl SMXXLWMICRQSSN-ZDUSSCGKSA-N 0.000 claims 1
- FHNIUCSNOQKWHS-HNNXBMFYSA-N n-[(2s)-1-amino-3-[2-(trifluoromethyl)phenyl]propan-2-yl]-5-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CC=C(C(=O)N[C@H](CN)CC=2C(=CC=CC=2)C(F)(F)F)N=C1 FHNIUCSNOQKWHS-HNNXBMFYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90874107P | 2007-03-29 | 2007-03-29 | |
| PCT/US2008/058603 WO2008121786A1 (en) | 2007-03-29 | 2008-03-28 | Inhibitors of akt activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010522770A JP2010522770A (ja) | 2010-07-08 |
| JP2010522770A5 true JP2010522770A5 (en:Method) | 2011-05-12 |
Family
ID=39808679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501246A Withdrawn JP2010522770A (ja) | 2007-03-29 | 2008-03-28 | Ａｋｔ活性の阻害物質 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8338434B2 (en:Method) |
| EP (1) | EP2134175A4 (en:Method) |
| JP (1) | JP2010522770A (en:Method) |
| WO (1) | WO2008121786A1 (en:Method) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| EP2358371B1 (en) * | 2008-10-31 | 2015-02-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| WO2010088331A1 (en) | 2009-01-30 | 2010-08-05 | Glaxosmithkline Llc | Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| WO2010094009A2 (en) * | 2009-02-13 | 2010-08-19 | Children's Hospital Medical Center | Methods and compositions for the treatment of ras associated disorders |
| EP2635279A4 (en) * | 2010-11-05 | 2014-10-29 | Glaxosmithkline Ip No 2 Ltd | CHEMICAL COMPOUNDS |
| US8895571B2 (en) | 2011-10-14 | 2014-11-25 | Incyte Corporation | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors |
| WO2013096153A1 (en) * | 2011-12-22 | 2013-06-27 | Glaxosmithkline Llc | Chemical compounds |
| WO2013096151A1 (en) * | 2011-12-22 | 2013-06-27 | Glaxosmithkline Llc | Chemical compounds |
| WO2013096637A1 (en) * | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| AU2014293011A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene |
| CN112888440A (zh) | 2018-10-16 | 2021-06-01 | 豪夫迈·罗氏有限公司 | Akt抑制剂在眼科中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04001088A (es) * | 2001-08-03 | 2004-05-20 | Vertex Pharma | Derivados de pirazol como inhibidores de cinasa y uso de los mismos. |
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| AU2003287366A1 (en) * | 2002-10-31 | 2004-06-07 | University Of Rochester | Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells |
| RU2342365C2 (ru) * | 2003-05-01 | 2008-12-27 | Бристол-Маерс Сквибб Компани | Арилзамещенные пиразоламиды в качестве ингибиторов киназ |
| CA2620818A1 (en) * | 2005-09-02 | 2007-03-08 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
-
2008
- 2008-03-28 WO PCT/US2008/058603 patent/WO2008121786A1/en not_active Ceased
- 2008-03-28 JP JP2010501246A patent/JP2010522770A/ja not_active Withdrawn
- 2008-03-28 US US12/593,415 patent/US8338434B2/en not_active Expired - Fee Related
- 2008-03-28 EP EP08744560A patent/EP2134175A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010522770A5 (en:Method) | ||
| JP2022185107A5 (en:Method) | ||
| JP2010518110A5 (en:Method) | ||
| JP2017522346A5 (en:Method) | ||
| JP2017508763A5 (en:Method) | ||
| JP2019531274A5 (en:Method) | ||
| JP2019521109A5 (en:Method) | ||
| JP2014526510A5 (en:Method) | ||
| RU2018146946A (ru) | Химические соединения | |
| JP2018507877A5 (en:Method) | ||
| JP2020506946A5 (en:Method) | ||
| JP2014508811A5 (en:Method) | ||
| JP2016539180A5 (en:Method) | ||
| RU2016141088A (ru) | 5-замещённые индазол-3-карбоксамиды и их получение и применение | |
| JP2020503297A5 (en:Method) | ||
| JP2015503529A5 (en:Method) | ||
| JP2013525458A5 (en:Method) | ||
| JP2016506964A5 (ja) | ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド | |
| JP2011126896A5 (en:Method) | ||
| JP2017530185A5 (en:Method) | ||
| WO2009107391A1 (ja) | ６員芳香環含有化合物 | |
| JP2015511629A5 (en:Method) | ||
| JP2017537948A5 (en:Method) | ||
| IL291590B2 (en) | Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | |
| JP2014527082A5 (en:Method) |